Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Inovio Pharmaceuticals, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
-60.64%
EBIT Growth (5y)
5.39%
EBIT to Interest (avg)
-110.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.28
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
59.95%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.62
EV to EBIT
-0.64
EV to EBITDA
-0.66
EV to Capital Employed
-1.76
EV to Sales
55.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-359.20%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Movement
8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -83.34 MM
NET PROFIT(HY)
Higher at USD -41.32 MM
RAW MATERIAL COST(Y)
Fallen by -99.9% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -477.7 %
-4What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 96.19 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 0 times
PRE-TAX PROFIT(Q)
Lowest at USD -23.9 MM
NET PROFIT(Q)
Lowest at USD -23.9 MM
Here's what is working for Inovio Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD -83.34 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at -477.7 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -99.9% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Inovio Pharmaceuticals, Inc.
Pre-Tax Profit
Lowest at USD -23.9 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -23.9 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 96.19 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio






